NEW YORK ( TheStreet) -- Investors rejoice but traders beware. Those were Jim Cramer's words to his "Mad Money" TV show viewers Friday, as he laid out his game plan for next week's trading. He explained that Friday's unemployment data could wipe out any gains for the week, but that will only give longer-term investors a chance to buy on the cheap. On Monday, Cramer said he'll be watching both HarmAn International ( HAR) and SBA Communications ( SBAC), two companies he expects will do well when they report. Tuesday brings Dominos Pizza ( DPZ) and Emerson Electric ( EMR), two companies Cramer was excited about, but also Cummins ( CMI) and Chesapeake Energy ( CHK), two companies Cramer was worried about. He advised taking profits in both names. Wednesday's earnings include Allergan ( AGN), Clorox ( CLX), Time Warner ( TWX), Garmin ( GRMN) and Continental Resources ( CLR), all companies Cramer said he'd be a buyer of. He was bearish on CVS Caremark ( CVS), which is losing customers to rival Walgreens ( WAG), and Green Mountain Coffee Roasters ( GMCR), a company with too many still unanswered questions. Then on Thursday, it's Airgas ( ARG), Teradata ( TDC) and AIG ( AIG), a stock Cramer owns for his charitable trust,
Executive DecisionIn the "Executive Decision" segment, Cramer spoke with T.J. Rodgers, president and CEO of Cypress Semiconductor ( CY), a stock that received a 10% haircut after it lowered expectations in the first quarter, but is still yielding 3%. Rodgers admitted to "screwing up" in the company's first quarter, albeit not as badly as they initially projected. That said, Rodgers noted that the company's guidance for the remainder of the year is conservative. "The only way for us to mess up now is to not execute," he concluded. Putting his money where his mouth is, Rodgers also noted that he recently purchased 500,000 shares of Cypress stock, a bullish gesture that Cramer said is not seen by many CEOs.
Turning to the company's business prospects, Rodgers said that buttons on gadgets will become obsolete, as touch interfaces will be the way humans interact with everything from their watch to their TV in the near future. That trend, said Rodgers, leaves huge opportunities for touch controllers that Cypress manufactures. He also touted the company's investment in Deca Technologies as being another huge opportunity for Cypress. Cramer said while the semiconductor business can be rocky from time to time, Rodgers has delivered in the past and Cypress pays a nice dividend while investors wait for the more lucrative back half of the year.
Upon Further ReviewIn the "Upon Further Review" segment, Cramer took a second look at the earnings of Kimberly-Clark ( KMB), a company that delivered a 7-cent-a-share earnings beat on a 4.2% increase in revenue. Cramer said while Kimberly delivered great earnings on its own, those earnings were even more spectacular when compared to those of its peers, like rival Procter & Gamble ( PG), which disappointed analysts for its second quarter in a row. While P&G appears to have lost its way, said Cramer, Kimberly, the makers of Kleenex tissues and Huggies diapers, has been taking share and growing organically. Kimberly executives were very upbeat on their conference call, noted Cramer, as the company continues to do well overseas. Latin America and Asia for example, now account for 35% of the company's sales and is growing rapidly. Increased sales, coupled with falling pulp and natural gas prices, are only adding to the company's success. Better still is valuation, noted Cramer. While Kimberly trades at just 14.2 times earnings, P&G trades at 15.6 times earnings and Colgate-Palmolive ( CL) trades at 19 times earnings. Given that Kimberly Clark is able to execute, is taking share and has a 3.75% dividend yield to boot, Cramer said the choice in the consumer staples arena is pretty clear.
Executive DecisionIn the second "Executive Decision" segment, Cramer spoke with Greg Lucier, chairman and CEO of Life Technologies ( LIFE), a biotech firm on the leading edge of DNA sequencing products. Lucier said that his company's latest gene sequencers will allow patients who get diagnosed with cancer on a Monday to be able to review their specific mutants that Tuesday, all for around $1,000. That will allow doctors to match patients with one of the 500 or so oncology drugs on the market that will work best for them.
When asked what the market potential could be for this technology, Lucier said the market opportunity is in the billions for just cancer patients alone and Life Technologies expects to sell thousands of its new machines. Lucier also responded to criticism that the company relies too heavily on government subsidies and research grants. He said those fears are largely overblown and even during times of budget cuts, the budget for this form of research will never fall to zero. Given that Life Technologies just posted a great first quarter on record sales, Cramer said the company remains a great investment, giving investors multiple ways to win.
here to sign up for Jim's Daily Booyah to get the Mad Money recap delivered to your inbox. For more of Cramer's insights during the Lightning Round, click here .